The Federal Trade Commission lost another battle in its war against “pay for delay” deals between brand name and generic drug makers on April 26 when the U.S. Court of Appeals for the Eleventh Circuit ruled that a settlement reached by the maker of AndroGel, a blockbuster treatment for low testosterone, did not violate federal antitrust laws.
The FTC alleged that the deal between AndroGel patent holder Solvay Pharmaceuticals Inc. now part of Abbotts Product Inc. and generic drug makers Watson Pharmaceuticals Inc. and Paddock Laboratories Inc./Par Pharmaceutical Companies Inc. was an unfair restraint of trade. The FTC asserted that the AndroGel patent was most likely invalid, and that Solvay’s payments to the generic rivals to hold off entering the market unlawfully protected its monopoly.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
